Spinal muscular atrophy (SMA) is a neurodegenerative disease caused by homozygous loss of the SMN1 gene. Copy number of the nearly identical paralog, SMN2, correlates with disease severity. SMN2 is the primary modifier of SMA, with only a few other modifiers reported. We reviewed the literature of rare siblings affected by SMA that show discordance in clinical presentation despite having the same number of SMN2 copies, which predicts the presence of genetic modifiers. We further recruited a sibling pair with discordant clinical presentations and performed detailed characterization. We utilized droplet digital PCR for deletion duplication testing and Sanger sequencing for full gene analysis of the SMN2 gene which confirmed zero copies of SMN1, four copies of SMN2, and no SMN2 modifying variants. Skin fibroblasts from each sibling were collected, reprogrammed into iPSCs, and differentiated to motor neurons. Patient-specific motor neurons revealed similar levels of SMN protein between the two siblings. Patient-specific iPSC-derived motor neurons collected from discordant siblings reported here may represent a powerful model for the discovery of SMN-independent modifiers.

The authors have declared no competing interest.

This work was supported by the Mayo Foundation for Medical Education and Research and Mayo Clinic Center for Regenerative Biotherapeutics. This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

IRB of Mayo Clinic gave ethical approval for this work.

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.

Yes

The data produced in the present study are not readily available because of ethical and privacy restrictions. Requests to access the data should be directed to the corresponding author.